Energy And Commerce Members Want FDA Overseas Operations Update
This article was originally published in The Rose Sheet
The GAO will report on foreign office closures and risk-based inspection policy amid Energy and Commerce leaders' concerns that an unequal playing field remains between domestic and foreign drug manufacturers.
You may also be interested in...
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.